Monoclonal RhD prophylaxis: high time to evaluate efficacy

Lancet. 2024 Mar 2;403(10429):806-807. doi: 10.1016/S0140-6736(23)01888-3.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't